Dementia Japan 31:57-66, 2017

Genomic biomarker for Alzheimer's disease

Ryozo Kuwano

Asahigawaso Research Institute, Asahigawaso Medical-Welfare Center

Biomarkers including genomic information are used to predict the development of dementia and a follow-up of an individual patient.  A number of risk SNPs, rare-variants and circulating miRNA are available by genome-wide association study and the next generation sequencing.  These genotype and phenotype data are essential for the personalized medicine.  By age 40, almost all Down syndrome, trisomy 21, have amyloid deposits in their brains, but not all individuals with of Down syndrome as well as the aged person in the general population develop dementia.  They have possible protective factors or pathways to circumvent the dementia.

Address correspondence to Dr. Ryozo Kuwano, Asahigawaso Research Institute, Asahigawaso Medical-Welfare Center (866 Gion, Kita-ku, Okayama 703-8555, Japan)